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AKTIVITI ANTIHIPERLIPIDEMIK DAN 
ANTIOKSIDAN EKSTRAK BAHAGIAN BERBEZA 
BAGI AVERRHOA CARAMBOLA DAN ELUSIDASI 
MEKANISME TINDAKANNYA 
 
ABSTRAK 
 
 
 
Averrhoa carambola, biasanya dikenali sebagai belimbing merupakan salah satu 
herba yang digunakan secara meluas dalam perubatan tradisional masyarakat 
Malaysia, daun dan buahnya merupakan bahagian yang paling banyak digunakan.  
Kajian ini bertujuan menyiasat kesan antihiperlipidemik, aktiviti anti-oksidan dan 
toksisiti ekstrak metanol dan akueus bahagian yang berlainan daripada A. carambola 
dengan tumpuan untuk elusidasi mekanisme tindakannya. Daripada semua ekstrak           
yang diuji, ekstrak metanol bahagian daun A. carambola menunjukkan aktiviti 
antihiperlipidemik terbaik dalam model tikus hiperlipidemik akut teraruh oleh 
poloxamer-407 berbanding kawalan hiperlipidemik yang setanding dengan aktiviti 
atorvastatin. Berikutan pemberian kronik sehingga lima minggu, tiada penurunan 
signifikan diperhatikan dalam aras parameter lipid bagi tikus normal yang dirawat 
dengan 1000 mg/kg ekstrak metanol daun. Sebaliknya, perbezaan yang signifikan 
diperhatikan dalam parameter lipid tikus hiperlipidemik teraruh diet tinggi lemak 
selepas dirawat dengan 500 dan 1000 mg/kg ekstrak metanol daun berbanding 
kawalan normal. Hasil kajian ini mencadangkan ekstrak metanol daun tersebut 
bertindak sebagai agen antihiperlipidemik dan bukan sebagai agen hipolipidemik. 
Selepas proses pemeringkatan, ujian menggunakan tikus hiperlipidemik akut teraruh 
oleh poloxamer-407 menunjukkan fraksi etil asetat bagi ekstrak methanol daun         
A. carambola mempamerkan kesan paling poten dalam penurunan semua parameter 
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lipid kecuali meningkatkan aras HDL-C. Bagi penilaian antioksidan, ekstrak metanol 
daun dan batang A. carambola menunjukkan aktiviti antioksidan paling tinggi. 
Kandungan fenolik dan flavonoid total bagi ekstrak A. carambola menunjukkan 
korelasi yang kuat dengan aktiviti antioksidan, tetapi tiada korelasi diperhatikan 
dengan kesan antihiperlipidemianya. Ekstrak metanol daun dan fraksi etil asetatnya 
menunjukkan kesan perencatan bergantungan dos ke atas enzim HMG-CoA 
reduktase pada kepekatan 5 dan 10 mg/mL, manakala kesan perencatan yang lemah 
dikesan pada enzim lipase pankreas in vitro. Tambahan lagi, ekstrak metanol daun 
meningkatkan aras enzim antioksidan in vivo secara signifikan dan menurunkan aras 
peroksidasi lipid dalam sampel serum dan homogenat hepar secara bergantungan 
dos. Selain itu, ekstrak metanol daun yang diberikan kepada tikus diet tinggi lemak 
pada dos 500 dan 1000 mg/kg menunjukkan keberkesanan dalam menurunkan 
penghasilan kolesterol dan trigliserida di dalam hepar dan meningkatkan 
perkumuhan kolesterol dan asid hempedu di dalam tinja. Penyiasatan menggunakan 
empat titisan sel kanser (K-562, HL-60, kasumi-1 dan HCT-116) mendapati kesemua 
ekstrak A. carambola tidak menunjukkan kesan sitotoksik. Kajian toksisiti akut dan 
sub-kronik menunjukkan ekstrak tersebut adalah selamat dan tiada perubahan 
signifikan diperhatikan bagi kedua-dua parameter biokimia dan hematologi dalam 
tikus rawatan berbanding kumpulan kawalan. Secara keseluruhannya, kajian ini 
mencadangkan ekstrak metanol daun A. carambola mempunyai kesan penurunan 
lipid yang boleh dibangunkan selanjutnya sebagai agen antihiperlipidemik. 
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ANTIHYPERLIPIDAEMIC AND ANTIOXIDANT 
ACTIVITIES OF EXTRACTS OF DIFFERENT PARTS 
OF AVERRHOA CARAMBOLA AND ELUCIDATION OF 
THEIR MECHANISMS OF ACTION 
 
ABSTRACT 
Averrhoa carambola, commonly known as star fruit is one of the widely used herbs 
in the Malaysian traditional medicine, with the leaf and fruits being the most utilized 
parts. This study aims to investigate the antihyperlipidaemic effect, antioxidant 
activity and toxicity of methanolic and aqueous extracts of different parts of             
A. carambola with focus on elucidating the underlying mechanism of action.           
Of the tested extracts, the methanolic extract of A. carambola leaf showed the most 
potent antihyperlipidaemic activity in poloxamer-407-induced acute hyperlipidaemic 
rat model compared to the hyperlipidaemic control, which was comparable with that 
of atorvastatin. Upon chronic administration up to five weeks, no significant decrease 
was observed in the levels of the lipid parameters of normal rats treated with         
1000 mg/kg of methanolic extract of leaf. In contrast, significant changes were 
observed in lipid parameters of high-fat diet induced hyperlipidemic rats after treated 
with 500 and 1000 mg/kg leaf methanolic extract as compared with the 
hyperlipidaemic control. These findings thus suggest that methanolic extract of        
A. carambola leaf works as an antihyperlipidaemic rather than a hypolipidaemic 
agent. Following fractionation, assessment using poloxamer-407 induced acute 
hyperlipidaemic rats showed that the ethyl acetate fraction of methanolic extract of 
A. carambola leaf exhibits the most potent significant effect in terms of reducing all 
lipid parameters except increasing high density lipoprotein cholesterol (HDL-C) 
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levels. For antioxidant evaluation, methanolic extract of A. carambola stem and leaf 
showed the highest antioxidant activity. The total phenolic and flavonoid contents of             
A. carambola extracts showed strong correlation with their antioxidant activities, but 
no correlation was found with their antihyperlipidaemic effects. Methanolic extract 
of leaf and its ethyl acetate fraction produced dose-dependent inhibitory effects on 
HMG-CoA reductase at 5 and 10 mg/mL concentrations, while weak inhibitory 
effect was detected on pancreatic lipase in vitro. In addition, methanolic extract of 
the leaf significantly increased the in vivo antioxidant enzymes levels and decreased 
the lipid peroxidation in liver homogenates and serum samples in a dose-dependent 
manner. On the other hand, methanolic extract of leaf given to high fat-diet rats at the 
doses of 500 and 1000 mg/kg was effective in reducing the synthesis of cholesterol 
and triglycerides in the liver and increasing the excretion of cholesterol and bile acids 
in faeces. An investigation using four cancer cell lines (K-562, HL-60, kasumi-1 and 
HCT-116) revealed that none of A. carambola extracts had cytotoxic effects. Acute 
and sub-chronic toxicity study of methanolic extract of A. carambola leaf showed 
that the extract was safe and no significant changes was observed in both 
biochemical and haematological parameters in treated rats compared with control 
group. Overall, this study suggests that the methanolic extract of A. carambola leaf 
has lipids lowering effect that could be further developed as an antihyperlipidaemic 
agent. 
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CHAPTER 1 
 
INTRODUCTION 
1.1  Background 
Cardiovascular diseases (CVDs) are responsible for the highest burden of disease 
globally (Merriel et al., 2014). They are the leading causes of death, morbidity and 
health expenses in developed and developing countries accounting around 30 % of 
the annual global mortality and 10 % of worldwide health burden (Deales et al., 
2013; Nair and Wang, 2013). Despite of having several therapeutic measures, focus 
has now been given for establishing effective preventive strategy for detecting and 
controlling of cardiovascular risk factors (O'Donnell and Elosua, 2008; Valdés et al., 
2014). 
Cardiovascular risk factors include a set of plasma lipids such as triglycerides 
(TG), total cholesterol (TC), very low density lipoprotein-cholesterol (VLDL-C), low 
density lipoprotein-cholesterol (LDL-C) and anti-atherogenic or high density 
lipoprotein-cholesterol (HDL-C) (Alzaid et al., 2014; Nelson, 2013). Dyslipidaemia 
is a highly heterogeneous class of metabolic disorders which is characterized by 
abnormalities in serum levels of various lipoproteins. The abnormalities of 
lipoproteins include elevation in TC, LDL-C and TG along with reduction in HDL-
C. It is a powerful risk factor for coronary heart disease (CHD) (Cahalin et al., 2013; 
Pratt et al., 2014). Etiologically, dyslipidaemia relies on specific metabolic 
backgrounds such as insulin resistance, thyroid dysfunction and defects in the 
gastrointestinal absorption of cholesterol and lipids, as well as mutations in cell 
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surface receptors and enzymes (Yadav et al., 2014).  Additionally, dyslipidaemia 
could occur because of suboptimal diet, obesity, inactive life style, genetic deviations 
and metabolism abnormalities (Xu et al., 2014). 
An increase in plasma lipids concentrations (TC, TG, LDL-C, and VLDL-C) 
or decreased in HDL-C levels beyond certain level give rise to physiological 
condition known as hyperlipidaemia which is the widest form of dyslipidaemia 
worldwide. It has also been reported to be the most widespread marker for 
susceptibility to atherosclerotic heart disease (Chen et al., 2014). Oxidative 
modification of LDL-C, protein glycation, glucose-auto-oxidation with production of 
free radicals and lipid peroxidation products are the main factors responsible for 
ischemic heart diseases which occurs as a result of hyperlipidaemia (Yang et al., 
2008).  
High levels of plasma lipids, mainly cholesterol, are a common feature of 
atherosclerosis, a condition in which arterial damage can lead to ischemic heart 
disease, myocardial infarction and cerebrovascular coincidences (Prasad et al., 2012). 
Hypercholesterolaemia and hypertriglyceridaemia are important risk factors, either 
alone or together. It was found that they are extensively contributing in the 
acceleration of the manifestation and development of coronary heart disease as well 
as the progression of atherosclerosis (Cahalin et al., 2013; Merriel et al., 2014).  
Accumulation of high levels of LDL-C in the extracellular sub-endothelial 
space of arteries is highly atherogenic and toxic to vascular cells which may lead to 
atherosclerosis, hypertension, obesity, diabetes and functional depression in some 
organs (Catapano et al., 2000; Jain et al., 2010). Several studies documented that 
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there is an obvious correlation between high cholesterol level in serum and 
cardiovascular disease (Bays et al., 2001). According to the American Heart 
Association report in 2004, heart disease and stroke will become the leading cause of 
death and disability worldwide. It is estimated that, by 2030, more than 24 million 
per year will suffer from the cardiovascular problems (Reinhardt, 2005). Globally, 
each year approximately 12 million people die due to cardiovascular diseases. 
Factors such as diet high in saturated fats and cholesterol, age, family history, 
hypertension and life style are of great significance but high level of cholesterol, 
particularly LDL-C is mainly responsible for the occurrence of CHD (Farias et al., 
1996).  
1.2 Therapeutic challenges 
Hyperlipidaemia has risen to the top in terms of causes of death in both developed 
and developing countries (Sunil et al., 2012). In Malaysia, the prevalence rate of 
hypercholesterolaemia accounts about 35.1 % (6.2 million) of adults (18 years and 
above) in which 8.4 % are known to have hypercholesterolaemia and 26.6 % are 
previously undiagnosed with hypercholesterolaemia (NHMS, 2011). There are 
various classes of synthetic lipid lowering agents used in current therapy belonging 
to the statins, fibrates or bile acid sequestrants groups. Although, they possess 
beneficial therapeutic effects, they are often associated with some serious side effects 
such as rhabdomyolysis, myopathy, elevation of hepatic enzyme levels and an 
increasing risk of gallstones (Javed et al., 2006; Laurance and Bennett, 1992; Shin et 
al., 2014).Thus, there is an exigent need for new lipid lowering agents with high 
therapeutic value and minimum tolerable side effects (Sefi et al., 2010; Shin et al., 
2014). 
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1.3 Problem statements 
Previously, a study among local plants indicated that different insoluble fibers 
prepared from Averrhoa carambola fruits have potential antihypocholesterolaemic 
activity (Wu et al., 2009). In addition, another study investigated the in vivo effect of 
micronized insoluble fiber and fiber-rich fraction from star fruit on lipids metabolism 
in a murine model (Herman-Lara et al., 2014).   
             However, to date there is neither detailed investigation on the lipid lowering 
effects of A. carambola nor report on the antihyperlipidaemic effect of other parts of 
A. carambola. This has created an interest to work on various parts of A. carambola 
to evaluate their antihyperlipidaemic effects and to further investigate the mechanism 
of action and toxicity. 
1.4 Objectives 
The objectives of the present study are: 
 
i. to evaluate the antihyperlipidaemic effects of methanolic and aqueous extracts of 
different parts of A. carambola and the fractions of the most active extract in 
chemically-induced acute hyperlipidaemic rats model 
ii. to evaluate the antihyperlipidaemic effect of the most active extract of                    
A. carambola in diet-induced chronic hyperlipidaemic rats model 
iii. to evaluate the antioxidant activity of methanolic and aqueous extract of different 
parts of A. carambola and the fractions of most active extract 
iv. to elucidate the mechanism of antihyperlidaemic effect of the most active extract 
of A. carambola and its bioactive fraction on 
a. inhibition of enzyme involved in lipids synthesis  
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b. lipids and bile acids absorption and excretion 
c. in vivo antioxidant and lipid peroxidation 
v. to investigate the toxicity of the most active extract of A. carambola 
vi. to standardize the most active extract of A. carambola using selected marker 
compound 
 
The research scheme is presented in figure 1.1.  
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1.5 Flow chart of the study 
  
 
    Figure 1.1: Flow chart of the study 
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CHAPTER 2 
 
LITERATURE REVIEW 
2.1 Lipids 
The term ‘‘Lipid’’ is imitative from ‘‘lipos’’, which refers to animal fat or vegetable 
oil. Adiposity is derived from ‘‘adipo’’ that denotes to body fat (Driskell, 2009). 
Utmost amounts of body lipids are stored in the adipocytes and adipose tissue 
including triglycerides and free cholesterol (Bays et al., 2013). The term lipids also 
refer to an entire class of fats and fat-like substances in the blood. The most essential 
lipids in the body include; fatty acids (FA), cholesterol, cholesterol esters, TGs and 
phospholipids (PLs). 
2.1.1 Fatty acids 
Fats are defined mainly as carboxylic acids (esters) with long hydrocarbon chains 
which are either saturated or unsaturated. Mostly, they are derived 
from triglycerides or phospholipids. They are named "free" fatty acids because of not 
attached to the other molecules.  They represent an important source of energy 
because they yield large quantities of ATP when metabolized (Ibrahim et al., 2013).  
 
 
      OH
O
 
 
1 Free fatty acid 
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2.1.2 Phospholipids 
Phospholipids (PLs) resemble the TG with small different in which one fatty acid in 
TG is replaced by phosphate and a nitrogenous base (Ibrahim et al., 2013). 
    
O
O
O
O
O
P
O
-O
O
N+
 
 
    2 Phospholipids     
 
2.1.3 Triglycerides 
Triglycerides (TG) are esters consisting of a glycerol molecule attached to three fatty 
acid residues. It could be found in dietary fats and can be synthesized in the liver and 
adipose tissue (Phan and Tso, 2001). It offers a source of stored energy when it is 
required, especially in case of starvation. It is found in all plasma lipoproteins and 
are the major component of lipoproteins with density less than 1.019 kg/L (Rosenson 
et al., 2002). The ideal or normal value of TG is less than 150 mg/dL (1.69 mmol/L) 
and values between 150 to 199 mg/dL is considered at the borderline high, while       
a values from 200 to 499 mg/dL  are high and above that considered very high 
(Ducharme and Radhamma, 2008, Raza et al., 2004). They are atherogenic because 
they are rich in apo C-III, which delays the lipolysis of VLDL and inhibits its uptake 
and clearance from plasma (Poirier et al., 2006). 
H
CH
CH O
CH
H
O
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O
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3 Triglycerides 
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2.1.4 Cholesterol and cholesterol esters 
Cholesterol and cholesterol esters are important elements found in all human cell 
membranes. Cholesterol is an essential constituent of steroid hormones and bile 
acids. They could be synthesized in liver and many tissues as well as may be 
acquired from dietary fat. Their main functions are to build, repair cells and produce 
hormones such as oestrogen and testosterone (Rudel et al., 2005). In addition, they 
modulate cell membrane fluidity and work as a precursor of bile acids, which play an 
important role in the digestion of fats (Ahmed et al., 2009). 
Cholesterol molecule is an amphipathic lipid, due to the presence of 
hydrophilic group (3β-hydroxyl group) attached to the hydrophobic part of the 
molecule. In addition to polarity, the 3β-hydroxyl reduces cholesterol ability to form 
esters (Pikuleva and Curcio, 2014). The desired value of TC is less than 200 mg/dL 
(5.17 mmol/L) and value between 200 to 239 mg/dL (5.17-6.18 mmol/L) is 
considered at the borderline high, while a value of 240 mg/dL(6.21 mmol/L) or more 
is high (Ducharme and Radhamma, 2008). 
Cholesterol is stored in the cells in the form of cholesteryl esters (one 
cholesterol molecule bound to one fatty acid by an ester bond). Esterification is 
carried out by Acyl-CoA: cholesterol acyltransferase (ACAT) 1 and 2. ACAT 1 is 
universally expressed, while ACAT 2 is expressed only in enterocytes and 
hepatocytes. Esteriﬁcation of cholesterol will produce a different shape molecule, 
which is greater in size and hydrophobicity (Lemaire-Ewing et al., 2012; Rudel et al., 
2005). 
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Free cholesterol could be eliminated from the liver into the bile via the ATP-
binding cassette (ABC) G5/G8 heterodimer. The cholesterol ring structure formed is 
highly stable and not easily metabolized (Parini et al., 2004). Cholesterol and other 
types of fats cannot dissolve in the blood. Thus, they have to be transported by 
attachment to specific molecules called lipoproteins in order to form macromolecular 
complexes (Abrass, 2004). 
2.2 Lipoproteins 
Lipoproteins are macromolecule complexes, which consist of spherical particles 
containing a hundreds of lipids and protein molecules. The main functions of 
lipoproteins is carrying and transporting the plasma lipids (Kanakavalli et al., 2014). 
There are five major lipoproteins; each one has its own function: chylomicrons, 
VLDLs, intermediate-density lipoproteins (IDLs), LDL-C and HDL-C (Kanakavalli 
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et al., 2014, Von Zychlinski et al., 2014). Table 2.1 demonstrates the physical 
properties of lipoproteins and their contents of apolipoproteins (Babin and Gibbons, 
2009; Crook, 2012; Von Zychlinski et al., 2014). Apolipoproteins are known as 
protein components of the lipoproteins or apoproteins. They assist as cofactors for 
enzymes and ligands for receptors. Disturbances in lipid handling will occur if there 
is any defect happened in apolipoprotein metabolism (Ducharme and Radhamma, 
2008). 
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Table 2.1: Physical properties of plasma lipoproteins  
(Babin and Gibbons, 2009; Crook, 2012; Ducharme and Radhamma, 2008; Von 
Zychlinski et al., 2014) 
2.3 Bile acids 
Bile acids (BA) are functional compounds that simplify emulsiﬁcation, absorption, 
and transportation of fats and sterols in the liver and intestine through formation of 
soluble mixed micelles with lipids (Ye et al., 2013). Daily, in the liver of the adult 
human about 500 mg of cholesterol is transformed into BA (Staels et al., 2010).   
 Chylomicron VLDL-C IDL-C LDL-C HDL-C 
Source  Gut Liver VLDL-C VLDL-C 
via ILD-C 
Gut /liver 
Density g/mL <0.95 0.95-1.006 1.006-1.019 1.063-1.09 1.063-1.21 
Diameter nm 800-5000 300-800 250-350 180-280 50-120 
Desired values 
(mg/dL) 
Undetectable <30 mg/dL Undetectable <130 >40 
Borderline-high  
(mg/dL) 
Undetectable Undetectable Undetectable 130-159 40-59 
High  (mg/dL) Undetectable Undetectable Undetectable >160 ≥ 60 
Functions Transport 
exogenous TG 
& cholesterol 
from intestine 
to all cells and 
tissues 
Transport 
endogenous 
TG & 
cholesterol 
from intestine 
to all cells 
and tissues 
Formed 
during the 
conversion of 
VLDL-C to 
LDL-C 
Formed 
from 
VLDLs, 
they carry 
cholesterol 
from liver 
to the cells 
and tissues 
Transport 
endogenous 
cholesterol 
from the 
cells and 
tissues back 
to the liver 
(scavenger) 
Apolipoproteins A1,A4,B48, 
C1,C2,C3,E 
B100,C1,C2, 
C3,E 
B100,C1,C2, 
C3,E 
Abo B100 A1,A2,A4, 
C1, C2,C3,E 
Total lipid (%)  98 – 99 90 – 94 89 79 45 - 55 
Protein 1 8 10 20 50 
Cholesterol  4 25 32 55 20 
TGs 90 55 25 5 5 
PL 5 12 25 20 25 
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They are the cornerstones, which play vital role in maintenance of mammalian 
cholesterol homeostasis. The liver represents the unique source and site of BA 
formations (Cherrington et al., 2013). 
Besides their role in lipid digestion, bile acids also denature dietary proteins, 
enhancing their rate of cleavage by pancreatic proteolytic enzymes. Bile acids also 
possess antimicrobial activity which remain poorly understood (Liu et al., 2013b). 
Synthesis of bile acids requires a group of enzymes belonging to the cytochrome 
P450 (CYP450) superfamily (Alrefai and Gill, 2007). BA biosynthesis involves 
modification of the ring structure of cholesterol, oxidation and shortening of the side 
chain and lastly conjugation with an amino acid (Zwicker and Agellon, 2013). These 
modifications are paramount to increase the polarity and consequently the solubility 
of these molecules (Hofmann et al., 2010). 
Figure 2.1 illustrates the two main pathways of bile acids synthesis; the 
standard (classic) and the alternative pathway. The standard pathway is controlled by 
an enzyme encoded by cholesterol 7α-hydroxylase (CYP7A1) gene which is the rate 
limiting enzyme in bile acid synthesis. It catalyses and initiates the major pathway in 
cholesterol catabolism and bile acid synthesis (Alnouti et al., 2008, Ogawa et al., 
2013, Pols et al., 2011). 
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Figure 2.1: Simple outlines of the classic and alternative pathways in bile acids 
synthesis. (CYP7A1, cholesterol 7alpha-hydroxylase; CYP27A1, sterol 27-
hydroxycholesterol) (Adapted from Thomas et al., 2008a). 
The standard pathway initiates with hydroxylation of the 7α position in the 
cholesterol ring structure, which will end with the formation of either cholic acid 
(CA) or chenodeoxycholic acid (CDCA) (Hofmann, 2009). CA and CDCA constitute 
the two primary bile acids in humans. CA and CDCA share a common precursor;  
7α-hydroxy-4-cholestene-3-one (C4), which can be hydroxylated in the C12 position 
by sterol 12α-hydroxylase (CYP8B1) to form CA. Otherwise, without                       
12α-hydroxylation, it is converted to CDCA (Lake et al., 2013). The alternate 
pathway is commenced by sterol 27-hydroxylase (CYP27A1) and results in 
formation of CDCA. Small changes appear in the bile acid synthesis in mice 
compared with human. In mice, most of the synthesized CDCA is converted into 
muricholic acids (MCAs) (Alnouti et al., 2008). 
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2.4 Cholesterol biosynthesis 
Cholesterol is an essential constituent in the plasma membranes of the eukaryotic 
organisms and it acts as a precursor for the biosynthesis of some vitamins, steroid 
hormones and bile acids (Faust and Kovacs, 2014). The biosynthesis of cholesterol is 
initiated by the reaction of acetate with citrate to produce acetyl-coenzyme A (acetyl-
CoA). Then, two molecules of acetyl-CoA under the action of thiolase forms 
acetoacetyl-CoA.  Acetoacetyl-CoA is transformed to hydroxyl methylglutaryl-CoA 
(HMG-CoA) upon the effect of HMG-CoA synthase. The subsequent reduction of 
the thioester in HMG-CoA in the presence of HMG-CoA reductase produces 
mevalonate. HMG-CoA reductase enzyme is called the rate limiting enzyme and this 
step is called the rate-limiting step in cholesterol biosynthesis (Groen et al., 2014).  
Decarboxylation, dehydration and double phosphorylation of mevalonate 
provide isopentenyl pyrophosphate. Condensation of six isoprenyl moieties of 
isopentenyl pyrophosphate results in the triterpene squalene. In cholesterol 
biosynthesis process, NADPH is used as a cofactor in all reduction reactions. 
Epoxidation of squalene to squalene oxide and cyclization afford the steroid 
lanosterol (Burg and Espenshade, 2011). Conversion of lanosterol to cholesterol 
required 19 steps including threefold demethylation and double-bond isomerization 
(Figure 2.2). 
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Figure 2.2: Biosynthesis of cholesterol, triglycerides and phospholipids.  
(HMG-Co A, hydroxymethylglutrylco A reductase; LDL, low density lipoprotein; 
NADP, nicotinamide adenine dinucleotide phosphate; NADPH, reduced from of 
NADP) (Adpated from Groen et al., 2014). 
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2.5 Digestion and absorption of lipids 
Lipids digestion is initiated in the stomach and catalysed by lingual lipases, which 
are secreted by tongue glands. In the stomach, lingual and gastric lipases continue 
digestion and emulsification of dietary fat and fat-soluble vitamins. Emulsified lipids 
enter the duodenum and subsequently mix with bile and pancreatic juice to go 
through many chemical and physical changes and the emulsification continues beside 
hydrolysis to be prepared for the absorption throughout the intestinal wall (Phan and 
Tso, 2001).  
Pancreatic lipase, colipase and bile salts are working together to enhance the 
competence of lipid digestion and absorption. Decreased rate of lipid absorption in 
humans reflects the importance of bile. It was found that, the activity of pancreatic 
lipase could be inhibited through elevated concentrations of bile salts in the 
duodenum. Nevertheless, colipase plays a critical role in dietary lipids digestion and 
it could be restored the pancreatic lipase activity in vitro (Lowe, 2002). 
2.5.1 Digestion and absorption of cholesterol 
In the body, two types of cholesterol exist; endogenous, which is being produced in 
the liver and peripheral tissues and exogenous (dietary), which is absorbed from the 
intestine. Free sterol composed the most dietary cholesterol, while cholesterol esters 
represent only 10-15%. Cholesterol esters will be hydrolysed by cholesterol esterase 
to release free cholesterol for absorption (Nair and Wang, 2013, Van Heek et al., 
2000). About 400 mg of cholesterol being provided via human diet daily and around 
1g cholesterol is secreted by the liver (Siddiqi, 2008). Almost 50 % of the cholesterol 
is absorbed in the intestine and the residue is excreted in faeces (Clearfield, 2003). 
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Only non-esterified cholesterol can be combined into bile acid micelles and 
absorbed by enterocytes. Cholesterol enters bile salt micelles, and then it will be 
transported to the brush border of the enterocyte to be absorbed (Voshol et al., 2001). 
Cholesterol absorption depends on the presence of bile acids in the intestinal lumen 
and it related directly with the total bile acid pool (Voshol et al., 2001). 
Subsequently, cholesterol will be transferred to the unstirred water layer under the 
help of bile salt micelles (Moreau et al., 2002).  
2.5.1.1 Cholesterol and bile acid cross-talk 
There is an association between cholesterol and BA metabolism and control of 
various important processes. The literature confirmed the existing opinion that BA 
excretion represents the central route for eliminating cholesterol from the body 
(Briones et al., 1986, Groen et al., 2014, Kesaniemi et al., 1981, Zwicker and 
Agellon, 2013). Thus, it was found that loss of BA signiﬁcantly contributes to 
cholesterol turnover. Nevertheless, around 95 % of the BA present in the intestinal 
lumen is reabsorbed and the BA pool remains effective in the enterohepatic 
circulation. Consequently, it is concluded that removal of excess cholesterol is 
definitely not the main role of BA synthesis in whole body cholesterol metabolism 
(Dietschy, 1968, Zwicker and Agellon, 2013). In human, a cycling frequency of BA 
is about 4–5 cycles per day and in every cycle about 5 % of the BA pool is lost. As 
the faecal BA loss is adequately recompensed for by hepatic synthesis to maintain 
BA pool size, de novo synthesis of BA (0.5 g/day in human) is a quantitatively 
significant pathway to maintain cholesterol homeostasis (Lefebvre et al., 2009). 
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2.5.2 Cholesterol excretion 
Approximately, every day 1g of cholesterol is removed from the body which is 
approximately equal to the amount of absorbed and synthesized cholesterol. Almost, 
half of cholesterol is excreted in the faeces after conversion to bile acids in liver, and 
the remainder is excreted as free cholesterol. BAs serve to remove undesired 
cholesterol from the body and to aid in lipid digestion in the intestine (Nair and 
Wang, 2013). 7α-hydroxylase enzyme is the rate limiting enzyme of bile acid 
biosynthesis which converts cholesterol into 7-hydroxycholesterol. Then,                  
7-hydroxycholesterol is converted to one of the two primary bile acids, cholic acid 
and chenodeoxycholic acid. Bile acids are then delivered to the intestines where they 
aid in the absorption of lipids. In the intestine, intestinal bacteria act to modify some 
of bile acids to form secondary bile acids such as lithocholic acid and deoxycholic 
acid. However, the majority of bile acids delivered to intestine are recycled by 
reabsorption in the ileum and returned to the liver by enterohepatic circulation. In 
liver, glyco- and tauro-conjugate bile acids are formed and stored in gall bladder, 
from where they are released into the intestinal lumen for aid in the digestion and 
absorption process of fats or lipids (Nair and Wang, 2013). 
2.5.3 Digestion and absorption of triglycerides 
Pancreatic lipase is the enzyme responsible for digestion of TG, which starts in the 
upper part of the jejunum. The action of this enzyme breaks down the triglycerides in 
the micelles at positions 1 and 3 leaving two free fatty acids, glycerol and                  
a 2-monoglycol (2-MAG) (Soutar and Naoumova, 2007). The predominant form in 
which MAG is absorbed from the small intestine is the 2-MAG. The uptake of          
2-MAG from the small intestine is faster compared with the formation of 2-MAG 
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and 1-MAG through isomerization in an aqueous medium. Cholesterol esterase can 
also hydrolyse the acyl group at the sn-2 position to form glycerol and FFAs. FFAs 
are taken up from the intestinal lumen into the enterocytes and used for the 
biosynthesis of neutral fats (Ibrahim et al., 2013; Marks et al., 2003; Soutar and 
Naoumova, 2007;).  
2.5.4 Digestion and absorption of phospholipids 
In the lumen of the small intestine, phosphocholesterol (PC) is the major PL, which 
is found in mixed micelles that contain cholesterol and bile salts. Pancreatic 
phospholipase A2 (PLA2) with lipases secreted by the pancreas are responsible for 
the primary digestion process of PLs in response to food intake. These lipases 
interact with PLs at the sn-2 position to yield FFAs and lysophosphatidylcholine 
(Huggins et al., 2002). These products of lipolysis are removed from the water-oil 
interface when they are incorporated into the mixed micelles that form spontaneously 
when they interact with bile salts. PLA2 deficiency has a greater effect on the 
digestion of TG than that of PL hydrolysis (Huggins et al., 2002). It does not affect 
PL hydrolysis and absorption, possibly because its activity is compensated by other 
PLA2 enzymes (Richmond et al., 2001). 
2.6 Lipid metabolic pathways 
Generation and transport of lipids within the body are controlled through three main 
pathways which include; exogenous, endogenous and reverse cholesterol transport 
pathway (Ducharme and Radhamma, 2008). 
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2.6.1 Exogenous pathway 
The free fatty acids will be combined with glycerol to form triglycerides once the 
digestion and absorption of dietary fat is completed. Then, cholesterol is esterified by 
acyl-coenzyme A: cholesterol acyltransferase (ACAT) to form cholesterol esters 
(Ibrahim et al., 2013). Triglycerides and cholesterol are present in the intracellular as 
chylomicrons. In the blood circulation, at the capillaries of the adipose tissue and 
muscle cells, chylomicrons interact to release the triglycerides into the adipose tissue 
to be stored and made available according to the body’s energy needs (Crook, 2012).  
Pancreatic lipase enzyme secreted from the pancreas is a key enzyme 
responsible for absorption and hydrolysis of triglyceride in the small intestine into 
glycerol and fatty acids (Sugiyama et al., 2007). Hence, the inhibition of lipase 
activity can lead to suppression of triglyceride absorption in the small intestine which 
could prevent obesity (Sugiyama et al., 2007). The enzyme lipoprotein lipase (LPL) 
hydrolyzes the triglycerides and releases the free-fatty acids. Some of the 
components of the chylomicrons are ‘‘repackaged’’ into other lipoproteins; for 
example, some apolipoproteins are transferred to HDL and the remaining 
chylomicrons particles are removed from the plasma by way of chylomicrons 
remnant receptors found on the liver (Ducharme and Radhamma, 2008) (Figure 2.3). 
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Figure 2.3: Exogenous pathway of lipid metabolism.(CM, chylomicron; FFA, free 
fatty acids; LPL, lipoprotein  Lipase; CM-REM, chylomicron remnant; REM-R, 
remnant receptor; CH, cholesterol) (Adapted from Ibrahim et al., 2013). 
 
2.6.2 Endogenous pathway 
The endogenous pathway involves the liver-synthesizing lipoproteins. Triglycerides 
and cholesterol esters are packaged into VLDL particles and released into the blood 
circulation. Subsequently, fatty acids and glycerol will be released due to the 
hydrolysis of VLDL by tissue LPL (Groen et al., 2014). Once processed by LPL, the 
VLDL-C becomes a VLDL-C remnant. Most VLDL-C remnants are taken up by the 
liver by way of the LDL-C receptor and the remaining remnant particles become 
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IDL-C which is a smaller and denser lipoprotein than VLDL-C. Some IDL-C 
particles will be reabsorbed by the liver through the LDL-C receptor, whereas others 
are hydrolysed in the liver by hepatic triglyceride lipase to form LDL-C, which is 
smaller and denser particle than IDL-C (Rezen et al., 2011). 
LDL-C is considered the main carrier of circulating cholesterol within the 
body. It is used by extrahepatic cells for cell membrane and steroid hormone 
synthesis. Most LDL-C particles are taken up by LDL-C receptors in the liver and 
the remaining particles are removed by way of scavenger pathways at the cellular 
level (Nair and Wang, 2013). Thus, this process will lead to suppression of the 
synthesis of new LDL-C receptors in the cells and activates the enzyme ACAT, 
which is responsible for the esterification of free cholesterol into cholesterol ester 
and store cholesterol in the cell (Ducharme and Radhamma, 2008). 
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Figure 2.4: Endogenous pathway of lipid metabolism. (LPL, lipoprotein lipase; 
FFA, free fatty acids; VLDL, very low density lipoproteins; IDL, intermediate-
density lipoproteins; LDL, low density lipoproteins; LDLR, low density lipoproteins 
receptor; CH, cholesterol; TGs, triglycerides) (Adapted from Ibrahim et al., 2013). 
2.6.3 Reverse cholesterol transport pathway 
In this process, cholesterol is removed from the tissues and returned back to the liver. 
HDL-C plays the main role in the process of reverse cholesterol transport and in 
transferring of cholesteryl esters between lipoproteins (Groen et al., 2014). HDL-C, 
which is considered the smallest and the most dense lipoprotein particle is being 
formed through a maturation process in which the precursor particles (nascent HDL) 
secreted by the liver and intestine carry on through a series of conversions known as 
the HDL-C cycle to attract cholesterol from cell membranes and free cholesterol to 
the HDL particle core (Groen et al., 2014). 
